price
About
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Stock ticker
- DXCM
- Company
- DexCom, Inc.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- 14
- Launch date
- Apr 14, 2005
- Listed exchange
- NASDAQ
Financials
Summary: DXCM reported Revenue of 1.31B (+13.08%), beating expectations; EPS of 0.70 (+45.83%), beating expectations.
Dividends
DXCM conversion tables
 |  |
|---|---|
| 0.5 DXCM | 223.98 BRL |
| 1 DXCM | 447.96 BRL |
| 5 DXCM | 2,239.81 BRL |
| 10 DXCM | 4,479.63 BRL |
| |
|---|---|
| 0.5 BRL | 0.0011162 DXCM |
| 1 BRL | 0.0022323 DXCM |
| 5 BRL | 0.011162 DXCM |
| 10 BRL | 0.022323 DXCM |
More to explore
FAQ
DXCM is trading at R$447.96, -0.22% over the last 24 hours. Track live moves on the price chart at the top of this page.
The DXCM stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. DXCM is currently trading at R$447.96, -0.22% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on DXCM price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. DXCM's P/E ratio is currently 34.12 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from DXCM; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against DXCM's historical range and other companies in the Healthcare sector.
DexCom, Inc.'s market cap is currently 168.81B BRL. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.